The DOI matches its Crossref record; 227 of the 227 references it cites were found in a registry or an index.
p53 Family and Cellular Stress Responses in Cancer
Open accessAbstract
p53 is an important tumor suppressor gene, which is stimulated by cellular stress like ionizing radiation, hypoxia, carcinogens, and oxidative stress. Upon activation, p53 leads to cell-cycle arrest and promotes DNA repair or induces apoptosis via several pathways. p63 and p73 are structural homologs of p53 that can act similarly to the protein and also hold functions distinct from p53. Today more than 40 different isoforms of the p53 family members are known. They result from transcription via different promoters and alternative splicing. Some isoforms have carcinogenic properties and mediate resistance to chemotherapy. Therefore, expression patterns of the p53 family genes can offer prognostic information in several malignant tumors. Furthermore, the p53 family constitutes a potential target for cancer therapy. Small molecules (e.g., Nutlins, RITA, PRIMA-1, and MIRA-1 among others) have been objects of intense research interest in recent years. They restore pro-apoptotic wild-type p53 function and were shown to break chemotherapeutic resistance. Due to p53 family interactions small molecules also influence p63 and p73 activity. Thus, the members of the p53 family are key players in the cellular stress response in cancer and are expected to grow in importance as therapeutic targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · cited 1×
“MDM2 is also capable of inducing the ubiquitin-mediated proteasomal degradation of the tumor suppressor protein (61, 62).”
BackgroundMomand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047 · cited 1×
“Proc Natl Acad Sci U S A (2006) 103(22):8435–40.”
Identification and characterization of a new member of the TNF family that induces apoptosis
Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900
p21 in cancer: Intricate networks and multiple activities
Abbas, T., & Dutta, A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2657 · Cited by 2,712
Caspase Functions in Cell Death and Disease
McIlwain, D. R., Berger, T., & Mak, T. W. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008656 · Cited by 2,594
Suda, T., Takahashi, T., Golstein, P., & Nagata, S. (1993) · Cell · doi:10.1016/0092-8674(93)90326-l · Cited by 2,489
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Hypoxia-inducible factors and the response to hypoxic stress
Majmundar, A. J., Wong, W. J., & Simon, M. C. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.022 · Cited by 2,380
p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development
Yang, A., Schweitzer, R., Sun, D., Kaghad, M., Walker, N., Bronson, R. T., Tabin, C., Sharpe, A., Caput, D., Crum, C., et al. (1999) · Nature · doi:10.1038/19539 · Cited by 2,225
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis
Chipuk, J. E., Kuwana, T., Bouchier-Hayes, L., Droin, N. M., Newmeyer, D. D., Schuler, M., & Green, D. R. (2004) · Science · doi:10.1126/science.1092734 · Cited by 2,108 · cited 1×
“Furthermore, cytosolic p53 can activate pro-apoptotic proteins such as Bax and Bak through direct protein–protein interaction (18, 81, 82).”
BackgroundYang, A., Kaghad, M., Wang, Y., Gillett, E., Fleming, M. D., Dötsch, V., Andrews, N. C., Caput, D., & McKeon, F. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80275-0 · Cited by 2,085
The first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967
The cancer stem cell: premises, promises and challenges
Clevers, H. (2011) · Nature Medicine · doi:10.1038/nm.2304 · Cited by 1,923
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · cited 1×
“Restoration of p53 function in mice suffering from lymphomas or sarcomas has been shown to induce tumor regression (177, 178).”
Backgroundp53 Has a Direct Apoptogenic Role at the Mitochondria
Mihara, M., Erster, S., Zaika, A., Petrenko, O., Chittenden, T., Pancoska, P., & Moll, U. M. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00050-9 · Cited by 1,777
Kaghad, M., Bonnet, H., Yang, A., Creancier, L., Biscan, J.-C., Valent, A., Minty, A., Chalon, P., Lelias, J.-M., Dumont, X., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80540-1 · Cited by 1,637
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
Mutational hot spot in the p53 gene in human hepatocellular carcinomas
Hsu, I. C., Metcalf, R. A., Sun, T., Welsh, J. A., Wang, N. J., & Harris, C. C. (1991) · Nature · doi:10.1038/350427a0 · Cited by 1,534
Soft-Tissue Sarcomas, Breast Cancer, and Other Neoplasms: A Familial Syndrome?
LI, F. P., & FRAUMENI, J. F. (1969) · Annals of Internal Medicine · doi:10.7326/0003-4819-71-4-747 · Cited by 1,509
Sunburn and p53 in the onset of skin cancer
Ziegler, A., Jonason, A. S., Leffellt, D. J., Simon, J. A., Sharma, H. W., Kimmelman, J., Remington, L., Jacks, T., & Brash, D. E. (1994) · Nature · doi:10.1038/372773a0 · Cited by 1,497
Ouelle, D. E., Zindy, F., Ashmun, R. A., & Sherr, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90214-7 · Cited by 1,485
Free Radicals in Biology: Oxidative Stress and the Effects of Ionizing Radiation
Riley, P. A. (1994) · International Journal of Radiation Biology · doi:10.1080/09553009414550041 · Cited by 1,453
Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa
Bressac, B., Kew, M., Wands, J., & Ozturk, M. (1991) · Nature · doi:10.1038/350429a0 · Cited by 1,432
Chipuk, J. E., Moldoveanu, T., Llambi, F., Parsons, M. J., & Green, D. R. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.01.025 · Cited by 1,427
Stott, F. J. (1998) · The EMBO Journal · doi:10.1093/emboj/17.17.5001 · Cited by 1,167
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
Essential versus accessory aspects of cell death: recommendations of the NCCD 2015
Galluzzi, L., Bravo-San Pedro, J. M., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Alnemri, E. S., Altucci, L., Andrews, D., Annicchiarico-Petruzzelli, M., et al. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.137 · Cited by 1,002
Yang, A., Walker, N., Bronson, R., Kaghad, M., Oosterwegel, M., Bonnin, J., Vagner, C., Bonnet, H., Dikkes, P., Sharpe, A., et al. (2000) · Nature · doi:10.1038/35003607 · Cited by 990
Nucleolar Arf sequesters Mdm2 and activates p53
Weber, J. D., Taylor, L. J., Roussel, M. F., Sherr, C. J., & Bar-Sagi, D. (1999) · Nature Cell Biology · doi:10.1038/8991 · Cited by 940
Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis.
Laster, S. M., Wood, J. G., & Gooding, L. R. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.141.8.2629 · Cited by 903
Kato, S., Han, S.-Y., Liu, W., Otsuka, K., Shibata, H., Kanamaru, R., & Ishioka, C. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1431692100 · Cited by 874
Caspase function in programmed cell death
Kumar, S. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402060 · Cited by 864
p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression
Lin, T., Chao, C., Saito, S., Mazur, S. J., Murphy, M. E., Appella, E., & Xu, Y. (2005) · Nature Cell Biology · doi:10.1038/ncb1211 · Cited by 859
p53 isoforms can regulate p53 transcriptional activity
Bourdon, J.-C., Fernandes, K., Murray-Zmijewski, F., Liu, G., Diot, A., Xirodimas, D. P., Saville, M. K., & Lane, D. P. (2005) · Genes & Development · doi:10.1101/gad.1339905 · Cited by 810
Pharmacological Rescue of Mutant p53 Conformation and Function
Foster, B. A., Coffey, H. A., Morin, M. J., & Rastinejad, F. (1999) · Science · doi:10.1126/science.286.5449.2507 · Cited by 799
DNA damage responses to oxidative stress
Barzilai, A., & Yamamoto, K.-I. (2004) · DNA Repair · doi:10.1016/j.dnarep.2004.03.002 · Cited by 796
Mutant p53 drives invasion by promoting integrin recycling
Muller, P. A. J., Caswell, P. T., Doyle, B., Iwanicki, M. P., Tan, E. H., Karim, S., Lukashchuk, N., Gillespie, D. A., Ludwig, R. L., Gosselin, P., et al. (2009) · Cell · doi:10.1016/j.cell.2009.11.026 · Cited by 796
A Mutant-p53/Smad Complex Opposes p63 to Empower TGFβ-Induced Metastasis
Adorno, M., Cordenonsi, M., Montagner, M., Dupont, S., Wong, C., Hann, B., Solari, A., Bobisse, S., Rondina, M. B., Guzzardo, V., et al. (2009) · Cell · doi:10.1016/j.cell.2009.01.039 · Cited by 782
Moll, U. M., & Petrenko, O. (2003) · PubMed · Cited by 780
Mitochondrial p53 activates Bak and causes disruption of a Bak–Mcl1 complex
Leu, J. I.-J., Dumont, P., Hafey, M., Murphy, M. E., & George, D. L. (2004) · Nature Cell Biology · doi:10.1038/ncb1123 · Cited by 770
The p53–Mdm2 module and the ubiquitin system
Michael, D., & Oren, M. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00099-8 · Cited by 765
Mutant p53 Gain-of-Function in Cancer
Oren, M., & Rotter, V. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001107 · Cited by 753
Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors
Issaeva, N., Bozko, P., Enge, M., Protopopova, M., Verhoef, L. G. G. C., Masucci, M., Pramanik, A., & Selivanova, G. (2004) · Nature Medicine · doi:10.1038/nm1146 · Cited by 750
The complexity of p53 stabilization and activation
Lavin, M. F., & Gueven, N. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401925 · Cited by 701
Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708917105 · Cited by 660
Vaseva, A. V., & Moll, U. M. (2009) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2008.10.005 · Cited by 618
Ultraviolet light induced injury: Immunological and inflammatory effects
Clydesdale, G. J., Dandie, G. W., & Muller, H. K. (2001) · Immunology & Cell Biology · doi:10.1046/j.1440-1711.2001.01047.x · Cited by 583
p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage
Yuan, Z.-M., Shioya, H., Ishiko, T., Sun, X., Gu, J., Huang, Y., Lu, H., Kharbanda, S., Weichselbaum, R., & Kufe, D. (1999) · Nature · doi:10.1038/21704 · Cited by 578
Transcriptional Regulation by P53
Beckerman, R., & Prives, C. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000935 · Cited by 569 · cited 2×
“The best characterized members of the death receptor family are TNFR1, CD95, DR3, TRAIL-R1 (CD4), TRAIL-R2 (CD5), and DR6 (39, 40).”
Backgroundp63 protects the female germ line during meiotic arrest
Suh, E.-K., Yang, A., Kettenbach, A., Bamberger, C., Michaelis, A. H., Zhu, Z., Elvin, J. A., Bronson, R. T., Crum, C. P., & McKeon, F. (2006) · Nature · doi:10.1038/nature05337 · Cited by 549
Cloning and functional analysis of human p51, which structurally and functionally resembles p53
Osada, M., Ohba, M., Kawahara, C., Ishioka, C., Kanamaru, R., Katoh, I., Ikawa, Y., Nimura, Y., Nakagawara, A., Obinata, M., et al. (1998) · Nature Medicine · doi:10.1038/nm0798-839 · Cited by 529
Murray-Zmijewski, F., Lane, D. P., & Bourdon, J.-C. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401914 · Cited by 523
Discovery, In Vivo Activity, and Mechanism of Action of a Small-Molecule p53 Activator
Lain, S., Hollick, J. J., Campbell, J., Staples, O. D., Higgins, M., Aoubala, M., McCarthy, A., Appleyard, V., Murray, K. E., Baker, L., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.03.004 · Cited by 522
p63 expression profiles in human normal and tumor tissues.
Como, C. J. D., Urist, M. J., Babayan, I., Drobnjak, M., Hedvat, C. V., Teruya‐Feldstein, J., Kamal, P., Hoos, A., & Cordon‐Cardo, C. (2002) · PubMed · Cited by 511
Flores, E. R., Sengupta, S., Miller, J. B., Newman, J. J., Bronson, R., Crowley, D., Yang, A., McKeon, F., & Jacks, T. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.019 · Cited by 502
Transcription-independent pro-apoptotic functions of p53
Moll, U. M., Wolff, S., Speidel, D., & Deppert, W. (2005) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2005.09.007 · Cited by 468
The p53 network: cellular and systemic DNA damage responses in aging and Cancer
Reinhardt, H. C., & Schumacher, B. (2012) · Trends in Genetics · doi:10.1016/j.tig.2011.12.002 · Cited by 458
GermlineTP53 mutations and Li-Fraumeni syndrome
Varley, J. M. (2003) · Human Mutation · doi:10.1002/humu.10185 · Cited by 430
TAp73 knockout shows genomic instability with infertility and tumor suppressor functions
Tomasini, R., Tsuchihara, K., Wilhelm, M., Fujitani, M., Rufini, A., Cheung, C. C., Khan, F., Itie-Youten, A., Wakeham, A., Tsao, M.-S., et al. (2008) · Genes & Development · doi:10.1101/gad.1695308 · Cited by 429
MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy
Kojima, K., Konopleva, M., Samudio, I. J., Shikami, M., Cabreira-Hansen, M., McQueen, T., Ruvolo, V., Tsao, T., Zeng, Z., Vassilev, L. T., et al. (2005) · Blood · doi:10.1182/blood-2005-02-0553 · Cited by 407
Watanabe, S., Tanaka, J., Ota, T., Kondo, R., Tanaka, H., Kagamu, H., Ichikawa, K., Koshio, J., Baba, J., Miyabayashi, T., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-1 · Cited by 394
Multiple C-Terminal Lysine Residues Target p53 for Ubiquitin-Proteasome-Mediated Degradation
Rodriguez, M. S., Desterro, J. M. P., Lain, S., Lane, D. P., & Hay, R. T. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.22.8458-8467.2000 · Cited by 389
Targeted rescue of a destabilized mutant of p53 by an in silico screened drug
Boeckler, F. M., Joerger, A. C., Jaggi, G., Rutherford, T. J., Veprintsev, D. B., & Fersht, A. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805326105 · Cited by 387
Uncovering the role of p53 splice variants in human malignancy: a clinical perspective
Bourdon, J.-C., Surget, S., & Khoury, M. P. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s53876 · Cited by 382
Transcription-independent p53 apoptosis: an alternative route to death
Speidel, D. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2009.10.002 · Cited by 356
Robertson, K. D., & Jones, P. A. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.11.6457 · Cited by 352
Inhibition of the c-Abl–TAp63 pathway protects mouse oocytes from chemotherapy-induced death
Gonfloni, S., Di Tella, L., Caldarola, S., Cannata, S. M., Klinger, F. G., Di Bartolomeo, C., Mattei, M., Candi, E., De Felici, M., Melino, G., et al. (2009) · Nature Medicine · doi:10.1038/nm.2033 · Cited by 346
(1999) · PubMed · Cited by 338
Jackson, J. G., Pant, V., Li, Q., Chang, L. L., Quintás-Cardama, A., Garza, D., Tavana, O., Yang, P., Manshouri, T., Li, Y., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.027 · Cited by 329
Barak, Y., Gottlieb, E., Juven-Gershon, T., & Oren, M. (1994) · Genes & Development · doi:10.1101/gad.8.15.1739 · Cited by 328
p63 and p73, the ancestors of p53
Dotsch, V., Bernassola, F., Coutandin, D., Candi, E., & Melino, G. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a004887 · Cited by 326
Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells
Yang, Y., Ludwig, R. L., Jensen, J. P., Pierre, S. A., Medaglia, M. V., Davydov, I. V., Safiran, Y. J., Oberoi, P., Kenten, J. H., Phillips, A. C., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.029 · Cited by 322
The ubiquitin–protein ligase Itch regulates p73 stability
Rossi, M., De Laurenzi, V., Munarriz, E., Green, D. R., Liu, Y., Vousden, K. H., Cesareni, G., & Melino, G. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600444 · Cited by 305
Dohn, M., Zhang, S., & Chen, X. (2001) · Oncogene · doi:10.1038/sj.onc.1204427 · Cited by 294
The Origins and Evolution of the p53 Family of Genes
Belyi, V. A., Ak, P., Markert, E., Wang, H., Hu, W., Puzio-Kuter, A., & Levine, A. J. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001198 · Cited by 292
A novel protein with strong homology to the tumor suppressor p53
Schmale, H., & Bamberger, C. (1997) · Oncogene · doi:10.1038/sj.onc.1201500 · Cited by 283
Regulated Cell Death: Signaling and Mechanisms
Ashkenazi, A., & Salvesen, G. (2014) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100913-013226 · Cited by 274
TAp63α induces apoptosis by activating signaling via death receptors and mitochondria
Gressner, O., Schilling, T., Lorenz, K., Schulze Schleithoff, E., Koch, A., Schulze‐Bergkamen, H., Maria Lena, A., Candi, E., Terrinoni, A., Valeria Catani, M., et al. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600708 · Cited by 255
PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis
Bykov, V. J. N., Zache, N., Stridh, H., Westman, J., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Oncogene · doi:10.1038/sj.onc.1208419 · Cited by 252
TAp63 induces senescence and suppresses tumorigenesis in vivo
Guo, X., Keyes, W. M., Papazoglu, C., Zuber, J., Li, W., Lowe, S. W., Vogel, H., & Mills, A. A. (2009) · Nature Cell Biology · doi:10.1038/ncb1988 · Cited by 251
Christmann, M., & Kaina, B. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt635 · Cited by 251
Tomita, Y., Marchenko, N., Erster, S., Nemajerova, A., Dehner, A., Klein, C., Pan, H., Kessler, H., Pancoska, P., & Moll, U. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m507611200 · Cited by 248
TAp73 enhances the pentose phosphate pathway and supports cell proliferation
Du, W., Jiang, P., Mancuso, A., Stonestrom, A., Brewer, M. D., Minn, A. J., Mak, T. W., Wu, M., & Yang, X. (2013) · Nature Cell Biology · doi:10.1038/ncb2789 · Cited by 233
Danger signalling during cancer cell death: origins, plasticity and regulation
Garg, A. D., Martin, S., Golab, J., & Agostinis, P. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.48 · Cited by 226
p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53
Melino, G. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2011.81 · Cited by 224
Ghioni, P., Bolognese, F., Duijf, P. H. G., van Bokhoven, H., Mantovani, R., & Guerrini, L. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.24.8659-8668.2002 · Cited by 223
Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation
Lin, A. W., & Lowe, S. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091100298 · Cited by 215
Mdm2 binds p73α without targeting degradation
Bálint, E., Bates, S., & Vousden, K. H. (1999) · Oncogene · doi:10.1038/sj.onc.1202781 · Cited by 212
Isoform-specific p73 knockout mice reveal a novel role for ΔNp73 in the DNA damage response pathway
Wilhelm, M. T., Rufini, A., Wetzel, M. K., Tsuchihara, K., Inoue, S., Tomasini, R., Itie-Youten, A., Wakeham, A., Arsenian-Henriksson, M., Melino, G., et al. (2010) · Genes & Development · doi:10.1101/gad.1873910 · Cited by 203
Reactivation of Mutant p53 and Induction of Apoptosis in Human Tumor Cells by Maleimide Analogs
Bykov, V. J. N., Issaeva, N., Zache, N., Shilov, A., Hultcrantz, M., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501664200 · Cited by 202
Kravchenko, J. E., Ilyinskaya, G. V., Komarov, P. G., Agapova, L. S., Kochetkov, D. V., Strom, E., Frolova, E. I., Kovriga, I., Gudkov, A. V., Feinstein, E., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802091105 · Cited by 191
Michaelis, M., Rothweiler, F., Barth, S., Cinatl, J., van Rikxoort, M., Löschmann, N., Voges, Y., Breitling, R., von Deimling, A., Rödel, F., et al. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.129 · Cited by 190
Reactivation of mutant p53: molecular mechanisms and therapeutic potential
Selivanova, G., & Wiman, K. G. (2007) · Oncogene · doi:10.1038/sj.onc.1210295 · Cited by 186
HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function
Lau, L. M. S., Nugent, J. K., Zhao, X., & Irwin, M. S. (2008) · Oncogene · doi:10.1038/sj.onc.1210707 · Cited by 182
Tran, M., Choi, W., Wszolek, M. F., Navai, N., Lee, I.-L. C., Nitti, G., Wen, S., Flores, E. R., Siefker-Radtke, A. O., Czerniak, B. A., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.408104 · Cited by 182
Müller, M., Schilling, T., Sayan, A. E., Kairat, A., Lorenz, K., Schulze-Bergkamen, H., Oren, M., Koch, A., Tannapfel, A., Stremmel, W., et al. (2005) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401774 · Cited by 171
Self-citationEnge, M., Bao, W., Hedström, E., Jackson, S. P., Moumen, A., & Selivanova, G. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.019 · Cited by 171
The two “hit” and multiple “hit” theories of carcinogenesis.
Ashley, D. J. (1969) · British Journal of Cancer · doi:10.1038/bjc.1969.41 · Cited by 168
DeltaNp73 regulates neuronal survival in vivo
Tissir, F., Ravni, A., Achouri, Y., Riethmacher, D., Meyer, G., & Goffinet, A. M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903191106 · Cited by 166
How theTP53Family ProteinsTP63andTP73Contribute to Tumorigenesis: Regulators and Effectors
Candi, E., Agostini, M., Melino, G., & Bernassola, F. (2014) · Human Mutation · doi:10.1002/humu.22523 · Cited by 166
One, two, three—p53, p63, p73 and chemosensitivity
MULLER, M., Schleithoff, E. S., Stremmel, W., Melino, G., Krammer, P. H., & Schilling, T. (2006) · Drug Resistance Updates · doi:10.1016/j.drup.2007.01.001 · Cited by 165
Ambrosini, G., Sambol, E. B., Carvajal, D., Vassilev, L. T., Singer, S., & Schwartz, G. K. (2007) · Oncogene · doi:10.1038/sj.onc.1210136 · Cited by 163
Vanbokhoven, H., Melino, G., Candi, E., & Declercq, W. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.84 · Cited by 161
CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death
Wischhusen, J., Naumann, U., Ohgaki, H., Rastinejad, F., & Weller, M. (2003) · Oncogene · doi:10.1038/sj.onc.1207198 · Cited by 158
Rufini, A., Agostini, M., Grespi, F., Tomasini, R., Sayan, B. S., Niklison-Chirou, M. V., Conforti, F., Velletri, T., Mastino, A., Mak, T. W., et al. (2011) · Genes & Cancer · doi:10.1177/1947601911408890 · Cited by 154
p63 steps into the limelight: crucial roles in the suppression of tumorigenesis and metastasis
Su, X., Chakravarti, D., & Flores, E. R. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3446 · Cited by 148
Locus-specific mutation databases: pitfalls and good practice based on the p53 experience
Soussi, T., Ishioka, C., Claustres, M., & Béroud, C. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1783 · Cited by 144
Overexpression of the wild type p73 gene in human bladder cancer
Yokomizo, A., Mai, M., Tindall, D. J., Liang Cheng, C., Bostwick, D. G., Naito, S., Smith, D. I., & Liu, W. (1999) · Oncogene · doi:10.1038/sj.onc.1202474 · Cited by 139
Targeting p53 for enhanced radio- and chemo-sensitivity
Lü, C., & El‐Deiry, W. S. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0330-1 · Cited by 138
TAp73 depletion accelerates aging through metabolic dysregulationPreprint
Rufini, A., Niklison-Chirou, M. V., Inoue, S., Tomasini, R., Harris, I. S., Marino, A., Federici, M., Dinsdale, D. D., Knight, R. A., Melino, G., et al. (2012) · Genes & Development · doi:10.1101/gad.197640.112 · Cited by 136
p53 directly transactivates Δ133p53α, regulating cell fate outcome in response to DNA damage
Aoubala, M., Murray-Zmijewski, F., Khoury, M. P., Fernandes, K., Perrier, S., Bernard, H., Prats, A., Lane, D. P., & Bourdon, J. (2010) · Cell Death and Differentiation · doi:10.1038/cdd.2010.91 · Cited by 136
Mangiulli, M., Valletti, A., Caratozzolo, M. F., Tullo, A., Sbisà, E., Pesole, G., & D’Erchia, A. M. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp674 · Cited by 135
Pharmacological reactivation of mutant p53: from protein structure to the cancer patient
Wiman, K. G. (2010) · Oncogene · doi:10.1038/onc.2010.188 · Cited by 134
Villalonga-Planells, R., Coll-Mulet, L., Martínez‐Soler, F., Castaño, E., Acebes, J.-J., Gimenez‐Bonafé, P., Gil, J., & Tortosa, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018588 · Cited by 132
Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3
Aziz, M. H., Shen, H., & Maki, C. G. (2011) · Oncogene · doi:10.1038/onc.2011.185 · Cited by 131
p53: The barrier to cancer stem cell formation
Aloni-Grinstein, R., Shetzer, Y., Kaufman, T., & Rotter, V. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.02.011 · Cited by 126
Wang, W., Takimoto, R., Rastinejad, F., & El-Deiry, W. S. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.6.2171-2181.2003 · Cited by 126
Δ160p53 is a novel N‐terminal p53 isoform encoded by Δ133p53 transcript
Marcel, V., Perrier, S., Aoubala, M., Ageorges, S., Groves, M. J., Diot, A., Fernandes, K., Tauro, S., & Bourdon, J.-C. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.10.005 · Cited by 125
Mdm2-mediated NEDD8 Modification of TAp73 Regulates Its Transactivation Function
Watson, I. R., Blanch, A., Lin, D. C. C., Ohh, M., & Irwin, M. S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603654200 · Cited by 124
Zalcenstein, A., Stambolsky, P., Weisz, L., Müller, M., Wallach, D., Goncharov, T. M., Krammer, P. H., Rotter, V., & Oren, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206724 · Cited by 123
A “Twist box” Code of p53 Inactivation: Twist box:p53 Interaction Promotes p53 Degradation
Piccinin, S., Tonin, E., Sessa, S., Demontis, S., Rossi, S., Pecciarini, L., Zanatta, L., Pivetta, F., Grizzo, A., Sonego, M., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.003 · Cited by 122
Duijf, P. H. G. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.7.799 · Cited by 121
Rowland, B. D., Denissov, S. G., Douma, S., Stunnenberg, H. G., Bernards, R., & Peeper, D. S. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00085-5 · Cited by 120
Beyer, U., Moll-Rocek, J., Moll, U. M., & Dobbelstein, M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016201108 · Cited by 117
The p53 Pathway as a Target in Cancer Therapeutics: Obstacles and Promise
Mandinova, A., & Lee, S. W. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001366 · Cited by 116
Ren, J., Datta, R., Shioya, H., Li, Y., Oki, E., Biedermann, V., Bharti, A. K., & Kufe, D. W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110667200 · Cited by 114
Helton, E. S., Zhu, J., & Chen, X. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507964200 · Cited by 114
The Role of BH3-Only Proteins in Tumor Cell Development, Signaling, and Treatment
Elkholi, R., Floros, K. V., & Chipuk, J. E. (2011) · Genes & Cancer · doi:10.1177/1947601911417177 · Cited by 114
The transcriptional activities of p53 and its homologue p51/p63: similarities and differences.
Shimada, A., Kato, S., Enjo, K., Osada, M., Ikawa, Y., Kohno, K., Obinata, M., Kanamaru, R., Ikawa, S., & Ishioka, C. (1999) · PubMed · Cited by 113
Gu, L., Zhu, N., Findley, H. W., & Zhou, M. L. (2008) · Leukemia · doi:10.1038/leu.2008.11 · Cited by 112
The C Terminus of p53 Family Proteins Is a Cell Fate Determinant
Harms, K. L., & Chen, X. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.5.2014-2030.2005 · Cited by 109
Screening for E3-Ubiquitin ligase inhibitors: challenges and opportunities
Landré, V., Rotblat, B., Melino, S., Bernassola, F., & Melino, G. (2014) · Oncotarget · doi:10.18632/oncotarget.2431 · Cited by 108
Olmos, Y., Brosens, J. J., & Lam, E. W. ‐. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.12.001 · Cited by 102
Zeng, X., Li, X., Miller, A., Yuan, Z.-M., Yuan, W., Kwok, R. P. S., Goodman, R. H., & Lu, H. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.4.1299-1310.2000 · Cited by 101
Δ40p53 controls the switch from pluripotency to differentiation by regulating IGF signaling in ESCsPreprint
Ungewitter, E. K., & Scrable, H. J. (2010) · Genes & Development · doi:10.1101/gad.1987810 · Cited by 101
The Regulation of the p53-mediated Stress Response by MDM2 and MDM4Preprint
Perry, M. E. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000968 · Cited by 101
p73 Regulates Neurodegeneration and Phospho-Tau Accumulation during Aging and Alzheimer's Disease
Wetzel, M. K., Naska, S., Laliberté, C. L., Rymar, V. V., Fujitani, M., Biernaskie, J., Cole, C. J., Lerch, J. P., Spring, S., Wang, S., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.07.021 · Cited by 98
Induction of p57 KIP2 expression by p73β
Bálint, É., Phillips, A. C., Козлов, С. В., Stewart, C. L., & Vousden, K. H. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.062491899 · Cited by 97
Seitz, S., Schleithoff, E. S., Koch, A., Schuster, A., Teufel, A., Staib, F., Stremmel, W., Melino, G., Krammer, P. H., Schilling, T., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24861 · Cited by 96
Self-citationSystems biology of death receptor networks: live and let die
Lavrik, I. N. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.160 · Cited by 93
Zhang, J., Cho, S. J., & Chen, X. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912594107 · Cited by 91
PRIMA-1Met/APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and Noxa
Saha, M. N., Jiang, H., Yang, Y., Reece, D., & Chang, H. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1166 · Cited by 91
p63 heterozygous mutant mice are not prone to spontaneous or chemically induced tumors
Keyes, W. M., Vogel, H. S., Koster, M. I., Guo, X., Qi, Y., Petherbridge, K. M., Roop, D. R., Bradley, A., & Mills, A. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602477103 · Cited by 88
Differential control of TAp73 and ΔNp73 protein stability by the ring finger ubiquitin ligase PIR2
Sayan, B. S., Yang, A. L., Conforti, F., Tucci, P., Piro, M. C., Browne, G. J., Agostini, M., Bernardini, S., Knight, R. A., Mak, T. W., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911828107 · Cited by 87
Atkins, K. M., Thomas, L. L., González, J. B., Thomas, L., Auclair, S., Yin, J., Kang, H., Chung, J. H., Dikeakos, J. D., & Thomas, G. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.07.049 · Cited by 87
p63/p73 in the control of cell cycle and cell death
Allocati, N., Ilio, C. D., & Laurenzi, V. D. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.01.023 · Cited by 86
p63 regulates glutaminase 2 expression
Giacobbe, A., Bongiorno‐Borbone, L., Bernassola, F., Terrinoni, A., Markert, E. K., Levine, A. J., Fen, Z., Agostini, M., Zolla, L., Finazzi‐Agrò, A., et al. (2013) · Cell Cycle · doi:10.4161/cc.24478 · Cited by 85
ΔNp63α Levels Correlate with Clinical Tumor Response to Cisplatin
Zangen, R., Ratovitski, E. A., & Sidransky, D. (2005) · Cell Cycle · doi:10.4161/cc.4.10.2066 · Cited by 84
Ding, J., Mooers, B. H. M., Zhang, Z., Kale, J., Falcone, D., Mcnichol, J., Huang, B., Zhang, X. C., Xing, C., Andrews, D. W., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.552562 · Cited by 83
Shalom‐Feuerstein, R., Serror, L., Aberdam, É., Müller, F.-J., van Bokhoven, H., Wiman, K. G., Zhou, H., Aberdam, D., & Petit, I. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201753109 · Cited by 83
PIAS-1 Is a Checkpoint Regulator Which Affects Exit from G1 and G2 by Sumoylation of p73
Munarriz, E. R., Barcaroli, D., Stephanou, A., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.24.10593-10610.2004 · Cited by 81
MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines
Ohnstad, H. O., Paulsen, E. B., Noordhuis, P., Berg, M., Lothe, R. A., Vassilev, L. T., & Myklebost, O. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-211 · Cited by 80
Kojima, K., Burks, J. K., Arts, J., & Andreeff, M. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0337 · Cited by 78
Wild-type p53 and p73 negatively regulate expression of proliferation related genes
Scian, M. J., Carchman, E. H., Mohanraj, L., Stagliano, K. E., Anderson, M. A. E., Deb, D., Crane, B., Kiyono, T., Windle, B. E., Deb, S., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210898 · Cited by 74
Knouf, E. C., Garg, K. S., Arroyo, J. D., Correa, Y., Sarkar, D., Parkin, R. K., Wurz, K., O'Briant, K. C., Godwin, A. K., Urban, N. D., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr731 · Cited by 74
Muller, P. A. J., Trinidad, A. G., Caswell, P. T., Norman, J. C., & Vousden, K. H. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.502138 · Cited by 73
Watanabe, K., Ozaki, T., Nakagawa, T., Miyazaki, K., Takahashi, M., Hosoda, M., Hayashi, S., Todo, S., & Nakagawara, A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111281200 · Cited by 71
Karakosta, A., Ch, G., Charalabopoulos, A., Peschos, D., Batistatou, A. K., & Charalabopoulos, K. (2005) · PubMed · Cited by 66
Gaiddon, C., Lokshin, M., Groß, I., Levasseur, D., Taya, Y., Loeffler, J., & Prives, C. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300251200 · Cited by 65
Tabernero, J., Dirix, L., Schöffski, P., Cervantes, A., Lopez-Martin, J. A., Capdevila, J., van Beijsterveldt, L., Platero, S., Hall, B., Yuan, Z., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1101 · Cited by 64
Sauer, M., Bretz, A. C., Beinoravičiūtė-Kellner, R., Beitzinger, M., Burek, M., Rosenwald, A., Harms, G. S., & Stiewe, T. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn044 · Cited by 64
Burmakin, M., Shi, Y., Hedström, E., Kogner, P., & Selivanova, G. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2211 · Cited by 63
Mutant p53 gain of function is interwoven into the hallmarks of cancer
Solomon, H., Madar, S., & Rotter, V. (2011) · The Journal of Pathology · doi:10.1002/path.2988 · Cited by 62
Conflicting Roles for p63 in Skin Development and Carcinogenesis
Koster, M. I., Dai, D., & Roop, D. R. (2007) · Cell Cycle · doi:10.4161/cc.6.3.3792 · Cited by 62
Targeting the Ubiquitin-Mediated Proteasome Degradation of p53 for Cancer Therapy
DeVine, T., & Dai, M. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319180009 · Cited by 62
Enhanced p73 Expression during Differentiation and Complex p73 Isoforms in Myeloid Leukemia
Tschan, M. P., Grob, T. J., Peters, U. R., Laurenzi, V. D., Huegli, B., Kreuzer, K., Schmidt, C. A., Melino, G., Fey, M. F., Tobler, A., et al. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3627 · Cited by 62
PRIMA-1MET/APR-246 targets mutant forms of p53 family members p63 and p73
Rökaeus, N., Shen, J., Eckhardt, I., Bykov, V. J. N., Wiman, K. G., & Wilhelm, M. (2010) · Oncogene · doi:10.1038/onc.2010.382 · Cited by 59
Evangelou, K., Bartkova, J., Kotsinas, A., Pateras, I. S., Liontos, M., Velimezi, G., Kosar, M., Liloglou, T., Trougakos, I. P., Dyrskjot, L., et al. (2013) · Cell Death & Differentiation · doi:10.1038/cdd.2013.76 · Cited by 59
p73-alpha is capable of inducing scotin and ER stress
Terrinoni, A., Ranalli, M., Cadot, B., Leta, A., Bagetta, G., Vousden, K. H., & Melino, G. (2004) · Oncogene · doi:10.1038/sj.onc.1207342 · Cited by 58
Wild Type p73 Overexpression and High-Grade Malignancy in Breast Cancer
Domínguez, G., Silva, J. M., Silva, J., Garcia, J. M., Sánchez, A., Navarro, A., Gallego, I., Provencio, M., España, P., & Bonilla, F. (2001) · Breast Cancer Research and Treatment · doi:10.1023/a:1010624717311 · Cited by 57
Therapeutic prospects for p73 and p63: Rising from the shadow of p53
Vilgelm, A. E., El-Rifai, W. M., & Zaika, A. I. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2008.08.001 · Cited by 54
Niklison-Chirou, M. V., Steinert, J. R., Agostini, M., Knight, R. A., Dinsdale, D. D., Cattaneo, A., Mak, T. W., & Melino, G. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221172110 · Cited by 52
Zauli, G., Celeghini, C., Melloni, E., Voltan, R., Ongari, M., Tiribelli, M., di Iasio, M. G., Lanza, F., & Secchiero, P. (2012) · Haematologica · doi:10.3324/haematol.2012.062083 · Cited by 52
Poly (C)-Binding Protein 1 Regulates p63 Expression through mRNA Stability
Cho, S.-J., Jung, Y.-S., & Chen, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071724 · Cited by 51
Pirh2 E3 Ubiquitin Ligase Modulates Keratinocyte Differentiation through p63
Jung, Y.-S., Qian, Y., Yan, W., & Chen, X. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.466 · Cited by 50
Differences in the transactivation domains of p53 family members: a computational study
Mavinahalli, J., Madhumalar, A., Beuerman, R. W., Lane, D. P., & Verma, C. S. (2010) · BMC Genomics · doi:10.1186/1471-2164-11-s1-s5 · Cited by 50
Rotblat, B., Grünewald, T. G. P., Leprivier, G., Melino, G., & Knight, R. A. (2013) · Oncotarget · doi:10.18632/oncotarget.1658 · Cited by 49
Gain-of-function p53 mutants have widespread genomic locations partially overlapping with p63
Martynova, E., Pozzi, S., Basile, V., Dolfini, D., Zambelli, F., Imbriano, C., Pavesi, G., & Mantovani, R. (2012) · Oncotarget · doi:10.18632/oncotarget.447 · Cited by 49
Zauli, G., Voltan, R., Bosco, R., Melloni, E., Marmiroli, S., Rigolin, G. M., Cuneo, A., & Secchiero, P. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2572 · Cited by 49
Wang, J., Zheng, T., Chen, X., Song, X., Meng, X., Bhatta, N., Pan, S., Jiang, H., & Liu, L. (2010) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06440.x · Cited by 45
Pruneri, G., Fabris, S., Dell’Orto, P., Biasi, M. O., Valentini, S., Curto, B. D., Laszlò, D., Cattaneo, L., Fasani, R., Rossini, L., et al. (2005) · The Journal of Pathology · doi:10.1002/path.1787 · Cited by 45
ΔNp63 knockdown mice: A mouse model for AEC syndrome
Koster, M. I., Marinari, B., Payne, A. S., Kantaputra, P. N., Costanzo, A., & Roop, D. R. (2009) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.32794 · Cited by 44
Active transcription of the human FAS/CD95/TNFRSF6 gene involves the p53 family
Schilling, T., Schleithoff, E. S., Kairat, A., Melino, G., Stremmel, W., Oren, M., Krammer, P. H., & Müller, M. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.07.063 · Cited by 43
Small molecules that bind the Mdm2 RING stabilize and activate p53
Roxburgh, P., Hock, A. K., Dickens, M. P., Mezna, M., Fischer, P. M., & Vousden, K. H. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs092 · Cited by 43
Nihal, M., Ahmad, N., & Wood, G. S. (2013) · Cell Cycle · doi:10.4161/cc.27523 · Cited by 43
Saha, M. N., Chen, Y., Chen, M.-H., Chen, G., & Chang, H. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.164 · Cited by 43
Mundt, H. M., Stremmel, W., Melino, G., Krammer, P. H., Schilling, T., & Müller, M. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.04.093 · Cited by 42
Self-citationp73 as a Pharmaceutical Target for Cancer Therapy
Bisso, A., Collavin, L., & Sal, G. D. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795222667 · Cited by 41
Kamb, A. (1994) · Nature · doi:10.1038/372730a0 · Cited by 41
Roh, J.-L., Ko, J. H., Moon, S. J., Ryu, C. H., Choi, J. Y., & Koch, W. M. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.05.020 · Cited by 41
Synthesis of 5-deazaflavin derivatives and their activation of p53 in cells
Wilson, J. M., Henderson, G., Black, F., Sutherland, A. J., Ludwig, R. L., Vousden, K. H., & Robins, D. J. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.10.011 · Cited by 40
Mir, R., Tortosa, A., Martínez‐Soler, F., Vidal, A., Condom, E., Pérez‐Perarnau, A., Ruiz‐Larroya, T., Gil, J., & Gimenez‐Bonafé, P. (2012) · International Journal of Cancer · doi:10.1002/ijc.27832 · Cited by 40
Burge, S., Teufel, D. P., Townsley, F. M., Freund, S. M. V., Bycroft, M., & Fersht, A. R. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900383106 · Cited by 40
MacCallum, S. F., Groves, M. J., James, J. L., Murray, K. E., Appleyard, V. C. L., Prescott, A. R., Drbal, A., Nicolaou, A., Cunningham, J., Haydock, S., et al. (2013) · Scientific Reports · doi:10.1038/srep01275 · Cited by 40
Cited by
Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy
Pal, A., & Kundu, R. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.03116 · Cited by 597
Major apoptotic mechanisms and genes involved in apoptosis
Kiraz, Y., Adan, A., Kartal Yandim, M., & Baran, Y. (2016) · Tumor Biology · doi:10.1007/s13277-016-5035-9 · Cited by 582
2-Deoxy-d-Glucose and Its Analogs: From Diagnostic to Therapeutic Agents
Pajak, B., Siwiak, E., Sołtyka, M., Priebe, A., Zieliński, R., Fokt, I., Ziemniak, M., Jaśkiewicz, A., Borowski, R., Domoradzki, T., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010234 · Cited by 574
Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer
Liu, G., Pei, F., Yang, F., Li, L., Amin, A., Liu, S., Buchan, J., & Cho, W. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020367 · Cited by 425
Maier, P., Hartmann, L., Wenz, F., & Herskind, C. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17010102 · Cited by 414
Metadata
- Authors
- Pflaum, J., Schlosser, S., & Müller, M.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2014-10-21
- Volume
- 4
- Pages
- 285-285
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2043157255
- Cited by
- 291
- References
- 227
- FWCI
- 13.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.